JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

@article{Schwemmers2007JAK2V617FnegativeEP,
  title={JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.},
  author={Sven Schwemmers and Britta Will and Cornelius F Waller and Khadija Abdulkarim and Peter Johansson and Bj{\"o}rn Andr{\'e}asson and Heike L Pahl},
  journal={Experimental hematology},
  year={2007},
  volume={35 11},
  pages={1695-703}
}
OBJECTIVE Presence of the JAK2V617F mutation in only 40% to 60% of patients with essential thrombocythemia (ET) underscores the heterogeneity of this myeloproliferative disorder (MPD). Several distinct mutations, either in JAK2 (exon 12) or in c-Mpl (W515L) have been described in subsets of other MPDs, polycythemia vera, and idiopathic myelofibrosis. Analogous to JAK2,V617F these mutations cause constitutive JAK2 and signal transducer and activation of transcription (STAT) activation. It has… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Aberrant expression of signaling proteins in essential thrombocythemia

Annals of Hematology • 2013
View 7 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…